Search results for "Lansoprazole"

showing 4 items of 4 documents

Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics

1997

AdultMalemedicine.medical_specialtyglossitiGlossitismedicine.drug_classAntibioticsadverse drug reactionLansoprazole2-PyridinylmethylsulfinylbenzimidazolesGlossitisPharmacotherapyTongueClarithromycinClarithromycinmedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)StomatitisAgedStomatitisbusiness.industryMiddle AgedAnti-Ulcer Agentsmedicine.diseaselansoprazoleDermatologyAnti-Bacterial Agentsmedicine.anatomical_structureDrug Therapy CombinationFemalebusinessclarythromicinOmeprazoleAdverse drug reactionmedicine.drug
researchProduct

Dexlansoprazole Delayed Release: Pharmacotherapy of Erosive Esophagitis and GERD

2011

Dexlansoprazole MR is a modified release formulation of the R-enantiomer of lansoprazole, which employs a novel Dual Delayed Release (DDR) technology. Pharmacokinetic studies have shown that the DDR technology provides a two peaks drug release, accuring 1–2 hours and 4–5 hours after dosing, leading to an extended duration of therapeutic plasma drug concentrations compared with conventional delayed release lansoprazole. Dexlansoprazole MR 30 and 60 mg provided superior intragastric pH control compared to that obtained with lansoprazole 15 mg and 30 mg once daily dosing. Dexlansoprazole can be taken without regard to food. The drug has been shown to be as efficacious as lansoprazole in heali…

PharmacologyDrugmedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectlcsh:RM1-950LansoprazolePharmaceutical ScienceGeneral Medicinemedicine.diseasePlaceboGastroenterologylcsh:Therapeutics. PharmacologyPharmacotherapyPharmacokineticsInternal medicineGERDmedicineDexlansoprazoleDosingbusinessmedia_commonmedicine.drugBiomedical engineeringClinical Medicine Insights: Therapeutics
researchProduct

Gold(I) compounds with lansoprazole-type ligands

2014

A number of gold(I) complexes containing the proton pump inhibitor (PPI) lansoprazole and its reduced precursor 2-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methylthio)-1H-benzo[d]imidazole have been synthesized and their biological effects have been evaluated in human cancer and nontumorigenic cells in vitro. The lansoprazole-based compounds appear to act through a V-H+-ATPase-mediated mechanism.

PharmacologyStereochemistryOrganic ChemistryLansoprazolePharmaceutical ScienceANTIPROLIFERATIVE PROPERTIESSERIESBiochemistryTUMORSIn vitroPROTON-PUMP INHIBITORSchemistry.chemical_compoundchemistryCHEMISTRYTARGETSDrug DiscoverymedicineMolecular MedicineImidazoleSOLUTION BEHAVIORCOMPLEXESAGENTSHuman cancerRESISTANCEmedicine.drugMedChemCommun
researchProduct

Pantoprazole: from drug metabolism to clinical relevance.

2008

Conditions requiring inhibition of acid secretion, such as gastro-oesophageal reflux disease (GORD), peptic ulcers, non-ulcer dyspepsia or the use of NSAIDs, are very common, and their prevalence is expecting to rise as they are seen predominantly amongst the elderly. Among the drugs available to inhibit acid secretion, proton pump inhibitors (PPI) have been shown to have the best efficacy-safety ratio and have been used widely.This paper was intended to provide an overall presentation of one of these PPIs, pantoprazole.This study was first intended to give an overview of pantoprazole, so a Medline search was conducted using pantoprazole as unique search term, without publication date restr…

medicine.medical_specialtyPeptic UlcerPepticRabeprazoleLansoprazoleToxicologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesEsomeprazoleInternal medicinemedicineHumansPantoprazoleOmeprazolePantoprazolePharmacologyClinical Trials as Topicbiologybusiness.industryProton Pump InhibitorsGeneral MedicineHelicobacter pyloribiology.organism_classificationAnti-Ulcer Agentsdigestive system diseasesTreatment OutcomeGastroesophageal RefluxbusinessDrug metabolismmedicine.drugExpert opinion on drug metabolismtoxicology
researchProduct